Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review – Regeneron

Written by

admin

in

  1. Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review  Regeneron
  2. Dupixent shows significant improvement for allergic fungal rhinosinusitis  Investing.com
  3. Dupixent meets all endpoints in allergic fungal rhinosinusitis study  Investing.com

Continue Reading

More posts